open access

Vol 11, No 5 (2016)
Review Papers
Published online: 2016-09-10
Get Citation

Hypertension and hypercholesterolemia treatment: combination of ACEI, calcium antagonist and statin

Katarzyna Starzyk, Beata Wożakowska-Kapłon
DOI: 10.5603/FC.a2016.0065
·
Folia Cardiologica 2016;11(5):427-432.

open access

Vol 11, No 5 (2016)
Review Papers
Published online: 2016-09-10

Abstract

Hypertension and hypercholesterolemia are the most common risk factors for cardiovascular events, in the Polish
population. Hypercholesterolemia is up on about 2/3, while hypertension is affecting about 1/3, of the adult Poles.
Both risk factors are poorly controlled in Polish patients. In order to improve the effectiveness of therapy and reduce
cardiovascular risk, combination drug theraphy without possibility of modyfication of component doses, should be
considered. The goal of cholesterol lowering treatment, with the use of first choice drug: statins, is LDL cholesterol
level. The majority of hipertensive patients requires two or more drugs to achieve the proper control of blood pressure, < 140/90 mm Hg. Application of more than one compounds in one preparation reduce the incidence of adverse effects and improves treatment adherence. The drug choice is important, because, for example, in an ASCOT study, combining the atorvastatin with perindopril and amlodypine, reduced the CV risk of 53%, but with atenolol and thiazid only of about 16%. Both hypertension and hypercholesterolemia impairs edothelial function, increase insulin resistance, summarize their negative impact. Theraphy with antihypertensives and statin combination is a good way to improve blood pressure and cholesterol control.

Abstract

Hypertension and hypercholesterolemia are the most common risk factors for cardiovascular events, in the Polish
population. Hypercholesterolemia is up on about 2/3, while hypertension is affecting about 1/3, of the adult Poles.
Both risk factors are poorly controlled in Polish patients. In order to improve the effectiveness of therapy and reduce
cardiovascular risk, combination drug theraphy without possibility of modyfication of component doses, should be
considered. The goal of cholesterol lowering treatment, with the use of first choice drug: statins, is LDL cholesterol
level. The majority of hipertensive patients requires two or more drugs to achieve the proper control of blood pressure, < 140/90 mm Hg. Application of more than one compounds in one preparation reduce the incidence of adverse effects and improves treatment adherence. The drug choice is important, because, for example, in an ASCOT study, combining the atorvastatin with perindopril and amlodypine, reduced the CV risk of 53%, but with atenolol and thiazid only of about 16%. Both hypertension and hypercholesterolemia impairs edothelial function, increase insulin resistance, summarize their negative impact. Theraphy with antihypertensives and statin combination is a good way to improve blood pressure and cholesterol control.

Get Citation

Keywords

ACEI, amlodypine, statin

About this article
Title

Hypertension and hypercholesterolemia treatment: combination of ACEI, calcium antagonist and statin

Journal

Folia Cardiologica

Issue

Vol 11, No 5 (2016)

Pages

427-432

Published online

2016-09-10

DOI

10.5603/FC.a2016.0065

Bibliographic record

Folia Cardiologica 2016;11(5):427-432.

Keywords

ACEI
amlodypine
statin

Authors

Katarzyna Starzyk
Beata Wożakowska-Kapłon

References (21)
  1. World Health Organisation Regional Office for Europe: mortality indicator database: mortality indicators by 67 causes of death, age and sex (HFA-MDB). . data.euro.who.int/hfamdb/ (05.01.2016).
  2. Bandosz P, O'Flaherty M, Drygas W, et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ. 2012: 344–354.
  3. Zdrojewski Ł, Zdrojewski T, Rutkowski M, et al. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol. 2013; 71(4): 381–392.
  4. Szostak-Węgierek D, Waśkiewicz A. Metabolic disorders in women at procreative age living in Warsaw. Rocz Panstw Zakl Hig. 2015; 66(3): 245–251.
  5. Jankowski P, Czarnecka D, Wolfshaut-Wolak R, et al. Secondary prevention of coronary artery disease in contemporary clinical practice. Cardiol J. 2015; 22(2): 219–226.
  6. Jardim TV, Sousa AL, Povoa TI, et al. The natural history of cardiovascular risk factors in health professionals: 20-year follow-up. BMC Public Health. 2015; 15: 1111–1118.
  7. Bandosz P, O'Flaherty M, Rutkowski M, et al. A victory for statins or a defeat for diet policies? Cholesterol falls in Poland in the past decade: A modeling study. Int J Cardiol. 2015; 185: 313–319.
  8. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–1681.
  9. De Vera MA, Bhole V, Burns LC, et al. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014; 78(4): 684–698.
  10. Starzyk K, Wożakowska-Kapłon B. Objawy mięśniowe w przebiegu stosowania statyn — fakty, mity, rzeczywistość i stanowiska ekspertów. Folia Cardiologica. 2015; 10(5): 354–360.
  11. Plakogiannis R, Cohen H. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration. Ann Pharmacother. 2007; 41(1): 106–110.
  12. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25): 2387–2397.
  13. Tykarski A, Narkiewicz K, Gaciong Z, et al. Guidelines for the Management of Hypertension. Arterial Hypertension. 2015; 19(2): 53–83.
  14. Zdrojewski T, Jankowski P, Bandosz P, et al. Nowa wersja systemu oceny ryzyka sercowo-naczyniowego i tablic SCORE dla populacji Polski. Kardiologia Polska. 2015; 73(10): 958–961.
  15. Wożakowska-Kapłon B, Filipiak K, Czarnecka D, et al. Miejsce leków złożonych w terapii nadciśnienia tętniczego — aktualne problemy w Polsce Stanowisko Ekspertów Polskiego Towarzystwa Nadciśnienia Tętniczego i Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiologia Polska. 2013; 71(4): 433–438.
  16. Kjeldsen SE, Julius S, Dahlöf B, et al. Physician (investigator) inertia in apparent treatment-resistant hypertension - insights from large randomized clinical trials. Lennart Hansson Memorial Lecture. Blood Press. 2015; 24(1): 1–6.
  17. Sever PS, Dahlöf B, Poulter NR, et al. ASCOT Investigators, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361(9364): 1149–1158.
  18. Sever P, Dahlöf B, Poulter N, et al. ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006; 27(24): 2982–2988.
  19. Starzyk K, Wożakowska-Kapłon B. Statyny w terapii chorego z nadciśnieniem tętniczym — czy tylko działanie hipolipemizujące? Arterial Hypertens. 2010; 14: 157–165.
  20. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012; 33(16): 2088–2097.
  21. Kluk MK, Wożakowska-Kapłon B. Perindopril — nieznane oblicza znanego leku. Folia Cardiol. 2014; 9: 173–178.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl